Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

| More on:
a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

Cochlear Ltd (ASX: COH) shares have been out of form recently.

For example, since the end of January, the hearing solutions company's shares have lost 15% of their value.

This leaves them trading much closer to their 52-week low than their 52-week high.

Is this a buying opportunity for investors? Let's take a look at what analysts are saying about this high quality company.

Are Cochlear shares a buy?

The team at Goldman Sachs sees value in its shares at current levels, but not quite enough to warrant a buy rating.

Its analysts currently have a neutral rating and $294.90 price target on Cochlear shares. Based on its current share price of $272.99, this implies potential upside of 8% over the next 12 months.

Goldman also expects a 1.6% dividend yield this year and next, which boosts the total potential return to almost 10%. Not bad for neutral! It said:

COH is the market leader in the manufacture and distribution of implantable hearing products, primarily cochlear implants (CI) but also bone-conduction implants. In our view, COH to date has executed well on its strategy and we forecast CI growth to step up from the investments to date in expanding the adults & seniors market.

Services growth however is likely to slow on the back of tighter funding requirements and with the stock trading close to our valuation we are Neutral rated. Key positive catalysts: Expanded reimbursement & COH product launches.

Elsewhere the team at Morgans has a hold rating and $285.55 price target on its shares and UBS has a neutral rating and $285.00 price target.

One bull

While the majority of brokers are sitting on the fence with their recommendations, there is one broker out there that is urging its clients to buy the dip.

According to a recent note out of Citi, its analysts have put a buy rating and $300.00 price target on its shares. Based on its current share price, this implies potential upside of 10%. This extends to approximately 12% when including dividends.

Citi believes that recent weakness has created a buying opportunity, highlighting that its shares are trading on lower than normal multiples. It also appears to see uncertainty regarding new product launches as priced in.

All in all, this could make it worth considering an investment in Cochlear shares while they are down in the dumps.

Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor James Mickleboro has positions in Cochlear. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear and Goldman Sachs Group. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

What are Cochlear shares worth according to Macquarie?

Let's see what the broker is saying about this blue chip.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

When will CSL shares finally catch a break?

Here's where analysts think the biotech stock is heading next.

Read more »

An analyst wearing a dark blue shirt and glasses sits at his computer with his chin resting on his hands as he looks at the CBA share price movement today
Healthcare Shares

JP Morgan initiates coverage of Telix Pharmaceuticals. After rising 1,667% in 5 years, is it still a buy?

Can this ASX 200 juggernaut go higher?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »

three excited doctors with hands in the air
Healthcare Shares

Two ASX healthcare shares that could be set to double

This broker has buy recommendations on these two shares. 

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Telix shares jump 7% on big US news

Let's see what is getting investors excited on Wednesday.

Read more »

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Macquarie tips 28% upside for this ASX healthcare stock

The broker expects big things from this New Zealand retirement village developer and operator.

Read more »